Literature DB >> 33246059

Inflammatory Cytokine IL-1β Downregulates Endothelial LRP1 via MicroRNA-mediated Gene Silencing.

Heng-Wei Hsu1, Carlos J Rodriguez-Ortiz1, Joannee Zumkehr1, Masashi Kitazawa2.   

Abstract

Effective clearance of neurotoxic amyloid-beta (Aβ) from the brain is a critical process to prevent Alzheimer's disease (AD). One major clearance mechanism is Aβ transcytosis mediated by low-density lipoprotein receptor-related protein 1 (LRP1) in capillary endothelial cells. A marked loss of endothelial LRP1 is found in AD brains and is believed to significantly impair Aβ clearance. Recently, we demonstrated that pro-inflammatory cytokines IL-1β, IL-6 and TNF-α, significantly down-regulated LRP1 in human primary microvascular endothelial cells (MVECs). In this study, we sought to determine the underlying molecular mechanism by which IL-1β led to LRP1 loss in MVECs. Reduced LRP1 protein and transcript were detected up to 24 h post-exposure and returned to the baseline levels after 48 h post-exposure with 1 ng/ml IL-1β. This reduction was in part mediated by microRNA-205-5p, -200b-3p, and -200c-3p, as these microRNAs were concomitantly upregulated in MVECs exposed to IL-1β. Synthetic microRNA-205-5p, -200b-3p, and -200c-3p mimics recapitulated LRP1 loss in MVECs without IL-1β, and their synthetic antagomirs effectively reversed IL-1β-mediated LRP1 loss. Importantly, we found that the expression of these three microRNAs was controlled by NF-κB as pharmacological NF-κB inhibitor, BMS-345541, inhibited the IL-1β-mediated upregulation of these microRNAs and rescued LRP1 expression. siRNA-mediated silencing of IκB in MVECs elevated microRNA-200b-3p and decreased LRP1 transcript, partially confirming our overall findings. In conclusion, our study provides a mechanism by which pro-inflammatory IL-1β instigates the suppression of LRP1 expression in MVECs. Our findings could implicate spatiotemporal loss of LRP1 and impairment of the LRP1-mediated clearance mechanism by endothelial cells.
Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; NF-κB; endothelial LRP1; interleukin-1β; microRNA; neuroinflammation

Mesh:

Substances:

Year:  2020        PMID: 33246059      PMCID: PMC7796931          DOI: 10.1016/j.neuroscience.2020.11.021

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  52 in total

1.  Copper-Induced Upregulation of MicroRNAs Directs the Suppression of Endothelial LRP1 in Alzheimer's Disease Model.

Authors:  Heng-Wei Hsu; Carlos J Rodriguez-Ortiz; Siok Lam Lim; Joannee Zumkehr; Jason G Kilian; Janielle Vidal; Masashi Kitazawa
Journal:  Toxicol Sci       Date:  2019-07-01       Impact factor: 4.849

2.  The effect of amyloid associated proteins on the expression of genes involved in amyloid-β clearance by adult human astrocytes.

Authors:  Sandra D Mulder; Robert Veerhuis; Marinus A Blankenstein; Henrietta M Nielsen
Journal:  Exp Neurol       Date:  2011-11-10       Impact factor: 5.330

3.  Amyloid efflux transporter expression at the blood-brain barrier declines in normal aging.

Authors:  Gerald D Silverberg; Arthur A Messier; Miles C Miller; Jason T Machan; Samir S Majmudar; Edward G Stopa; John E Donahue; Conrad E Johanson
Journal:  J Neuropathol Exp Neurol       Date:  2010-10       Impact factor: 3.685

4.  Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

Authors:  F Licastro; S Pedrini; L Caputo; G Annoni; L J Davis; C Ferri; V Casadei; L M Grimaldi
Journal:  J Neuroimmunol       Date:  2000-02-01       Impact factor: 3.478

5.  Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway.

Authors:  D E Kang; C U Pietrzik; L Baum; N Chevallier; D E Merriam; M Z Kounnas; S L Wagner; J C Troncoso; C H Kawas; R Katzman; E H Koo
Journal:  J Clin Invest       Date:  2000-11       Impact factor: 14.808

Review 6.  Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies.

Authors:  Mitsuru Shinohara; Masaya Tachibana; Takahisa Kanekiyo; Guojun Bu
Journal:  J Lipid Res       Date:  2017-04-04       Impact factor: 5.922

7.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Authors:  M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

8.  Chronic IL-1β-mediated neuroinflammation mitigates amyloid pathology in a mouse model of Alzheimer's disease without inducing overt neurodegeneration.

Authors:  Sarah B Matousek; Simantini Ghosh; Solomon S Shaftel; Stephanos Kyrkanides; John A Olschowka; M Kerry O'Banion
Journal:  J Neuroimmune Pharmacol       Date:  2011-12-16       Impact factor: 4.147

9.  Strong nuclear factor-kappaB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex.

Authors:  W J Lukiw; N G Bazan
Journal:  J Neurosci Res       Date:  1998-09-01       Impact factor: 4.164

10.  Sustained hippocampal IL-1beta overexpression impairs contextual and spatial memory in transgenic mice.

Authors:  Amy M Hein; Melissa R Stasko; Sarah B Matousek; Jonah J Scott-McKean; Steven F Maier; John A Olschowka; Alberto C S Costa; M Kerry O'Banion
Journal:  Brain Behav Immun       Date:  2009-10-13       Impact factor: 7.217

View more
  2 in total

Review 1.  The promise of microRNA-based therapies in Alzheimer's disease: challenges and perspectives.

Authors:  Hannah Walgrave; Lujia Zhou; Bart De Strooper; Evgenia Salta
Journal:  Mol Neurodegener       Date:  2021-11-06       Impact factor: 14.195

2.  TNF-α and IL-1β Modulate Blood-Brain Barrier Permeability and Decrease Amyloid-β Peptide Efflux in a Human Blood-Brain Barrier Model.

Authors:  Romain Versele; Emmanuel Sevin; Fabien Gosselet; Laurence Fenart; Pietra Candela
Journal:  Int J Mol Sci       Date:  2022-09-06       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.